[Efficacy of hepatic arterial infusion of adriamycin and mitomycin C mixed with degradable starch microspheres for liver metastasis of colorectal cancer--correlation with the mRNA expression of DNA topoisomerase-IIalpha and glutathione-S transferase-pi in primary lesions].
DNA topoisomerase-IIalpha (topo-IIalpha) is a target enzyme of adriamycin (ADM). Glutathione-S-transferase-pi is known to be correlated with the resistance of various anticancer drugs including mitomycin C (MMC) and ADM. Expression levels of topo-IIalpha and GST-pi mRNA of primary colorectal lesions were semi-quantitatively determined by the RT-PCR method in 22 patients with colorectal cancer, who underwent hepatic arterial infusion of ADM and MMC mixed with degradable starch microspheres for synchronous (n=17) or metachronous (n=5) liver metastasis. Expression of topo-IIalpha mRNA/beta-actin mRNA was 0.872+/-0.564 (mean+/-SD) in responders (PR, n=10) and 0.369+/-0.133 in non-responders (SD+PD, n=12) (p=0.047). The relative expression of GST-pi was 0.638+/-0.593 in responders and 1.014+/-0.682 in non-responders (p=0.22). These results suggest that determining the mRNA expression of topo-IIalpha is useful for predicting the efficacy for this regimen, whereas determining the mRNA expression of GST-pi is not.
Ishida
Hideyuki
H
Dept. of Surgery, Saitama Medical Center, Saitama Medical School.
Shirakawa
Kazuo
K
Takeuchi
Ikuya
I
Nakada
Hiroshi
H
Ohsawa
Tomonori
T
Hayashi
Yoichi
Y
Okada
Norimichi
N
Yokoyama
Masaru
M
Inokuma
Shigehisa
S
Hashimoto
Daijo
D
Osada
Hisato
H
Matsumoto
Yoshiro
Y
Miura
Tsuyoshi
T
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001673:Biodegradation, Environmental; D015179:Colorectal Neoplasms / Q000473:pathology*; D003131:Combined Modality Therapy; D004250:DNA Topoisomerases, Type II / Q000032:analysis* / Q000235:genetics; D004268:DNA-Binding Proteins; D004317:Doxorubicin / Q000008:administration & dosage; D004621:Embolization, Therapeutic / Q000379:methods*; D005260:Female; D051549:Glutathione S-Transferase pi; D005982:Glutathione Transferase / Q000032:analysis* / Q000235:genetics; D006499:Hepatic Artery; D006801:Humans; D007261:Infusions, Intra-Arterial; D007527:Isoenzymes / Q000032:analysis* / Q000235:genetics; D008113:Liver Neoplasms / Q000201:enzymology / Q000556:secondary* / Q000628:therapy*; D008297:Male; D008863:Microspheres; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D012333:RNA, Messenger / Q000032:analysis; D013213:Starch / Q000008:administration & dosage
D000951:Antigens, Neoplasm; D004268:DNA-Binding Proteins; D007527:Isoenzymes; D012333:RNA, Messenger; D016685:Mitomycin; D004317:Doxorubicin; D013213:Starch; C496556:GSTP1 protein, human; D051549:Glutathione S-Transferase pi; D005982:Glutathione Transferase; D004250:DNA Topoisomerases, Type II